Empagliflozin is effective in improving the clinical outcomes in patients with acute heart failure and low BP without further ...

With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...

Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.

There are several domestic drug companies that seem to be all prepared to transform diabetes therapy with the launch of the ...

Empagliflozin's price in India will drop from Rs 60 to Rs 9 per tablet as companies like Mankind Pharma, Torrent, and Lupin ...

While Metformin continues to be the standard first-line treatment for Type-2 diabetes, newer therapies such as SGLT2 ...

Currently priced at Rs 60 per tablet, Empagliflozin’s generic versions will be available for as low as Rs 9-Rs 14 per tablet, significantly reducing costs for millions of patients, states the report.

Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, ...

Domestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

The rate of any diabetes-related retinal diseases increased from 10.8% in 2014 to 20.8% in 2021, the findings have reported.